Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-25-061850
Filing Date
2025-05-01
Accepted
2025-05-01 16:15:17
Documents
59
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 6-K asnd-20250331.htm   iXBRL 6-K 1987926
2 GRAPHIC img149481191_0.jpg GRAPHIC 83968
3 GRAPHIC img149481191_1.jpg GRAPHIC 223137
4 GRAPHIC img149481191_2.jpg GRAPHIC 96521
5 GRAPHIC img149481191_3.jpg GRAPHIC 58992
6 GRAPHIC img149481191_4.jpg GRAPHIC 68861
7 GRAPHIC img149481191_5.jpg GRAPHIC 192422
8 GRAPHIC img149481191_6.jpg GRAPHIC 85287
9 GRAPHIC img149481191_7.jpg GRAPHIC 128430
10 GRAPHIC img149481191_8.jpg GRAPHIC 61198
  Complete submission text file 0000950170-25-061850.txt   9315388

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT asnd-20250331.xsd EX-101.SCH 1111914
61 EXTRACTED XBRL INSTANCE DOCUMENT asnd-20250331_htm.xml XML 1134992
Mailing Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900
Business Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900 45 70 22 22 44
Ascendis Pharma A/S (Filer) CIK: 0001612042 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36815 | Film No.: 25903295
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)